Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Fineline Cube Jul 16, 2026
Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Fineline Cube Jul 16, 2026
Company Medical Device

Boston Scientific Launches Athletis Peripheral Balloon Dilatation Catheter in China

Fineline Cube Jan 1, 2025

US-based medical device leader Boston Scientific Corporation (NYSE: BSX) has announced the market launch of...

Company Drug

Alphamab Oncology’s JSKN033 Advances to Phase III Trial for Platinum Resistant Ovarian Cancer

Fineline Cube Jan 1, 2025

China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...

Company Drug

Frontera Therapeutics Advances to Phase II with FT-003 for Diabetic Macular Edema

Fineline Cube Jan 1, 2025

Sino-US firm Frontera Therapeutics, Inc. has announced that it has received approval from the US...

Company Drug

Johnson & Johnson’s Rybrevant Combo Approved by EC for First-Line NSCLC Treatment

Fineline Cube Jan 1, 2025

US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that the European Commission...

Company Deals

BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312/BG-C9074

Fineline Cube Jan 1, 2025

Duality Biologics, a developer of antibody conjugate drugs (ADCs) with operations in the United States...

Company Drug

Novartis Announces Positive Results from Phase III STEER Study on SMA Treatment

Fineline Cube Jan 1, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced positive topline results from the Phase III...

Drug Medical Device Policy / Regulatory

10th National VBP Round Results Announced: Contracts Worth Over RMB1.3 Billion

Fineline Cube Dec 31, 2024

The national Volume-Based Procurement (VBP) authorities have released comprehensive details regarding the 10th VBP round,...

Company Deals

Xtalpi Inc. Partners with Amazon Web Services to Accelerate Life Sciences Innovation

Fineline Cube Dec 31, 2024

Shenzhen-based QuantumPharm Inc., operating under the name Xtalpi Inc. (HKG: 2228), has announced a strategic...

Company Drug

Jiangxi Jemincare Group Gets NMPA Approval for Prostate Cancer Drug JMX-2006

Fineline Cube Dec 31, 2024

China-based Jiangxi Jemincare Group has announced that it has received clinical trial approval from the...

Company Drug

CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2219 in China

Fineline Cube Dec 31, 2024

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the initiation of an investigator-initiated-trial (ITT)...

Company Deals

We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 31, 2024

China-based We Doctor Holdings Limited, a subsidiary of Chinese internet giant Tencent Corporate Venture Capital...

Company Deals

Shinva Medical Instrument to Acquire Stake in Wuhan Zhongzhi Biotechnologies for IVD Expansion

Fineline Cube Dec 31, 2024

China’s Shinva Medical Instrument Co., Ltd (SHA: 600587) has announced its intention to acquire a...

Company Drug

Hinova Pharmaceuticals’ HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer

Fineline Cube Dec 31, 2024

Chengdu-based biotech Hinova Pharmaceuticals Inc., (SHA: 688302) has announced that it has received clinical trial...

Company Drug

CanSino Biologics’ Menhycia Receives Market Approval in Indonesia

Fineline Cube Dec 31, 2024

China-based CanSino Biologics (HKG: 6185) has received market approval from the Badan Pengawas Obat dan...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for SYH9016 Clinical Study in Solid Tumors

Fineline Cube Dec 31, 2024

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

MicuRx Pharmaceuticals’ MRX-5 Receives FDA Orphan Drug Designation for NTM Infections

Fineline Cube Dec 30, 2024

Sino-US firm MicuRx Pharmaceuticals Inc. has announced that the US Food and Drug Administration (FDA)...

Company Deals

Hengrui Pharmaceuticals and IDEAYA Biosciences Ink Licensing Deal for SHR-4849

Fineline Cube Dec 30, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced a significant licensing agreement with US-based...

Company Drug

CARsgen Therapeutics’ Satricabtagene Autoleucel Shows Positive Results in Phase II Study

Fineline Cube Dec 30, 2024

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced positive results from its pivotal Phase...

Company Drug

argenx’s Vygart Hytrulo Approved in Japan for Chronic Inflammatory Demyelinating Polyneuropathy

Fineline Cube Dec 30, 2024

Holland-based argenx SE (NASDAQ: ARGX) has announced receiving another indication approval from Japan’s Ministry of...

Company Drug

Daiichi Sankyo’s Datroway Approved in Japan for HR+, HER2- Breast Cancer

Fineline Cube Dec 30, 2024

Japan-based pharmaceutical company Daiichi Sankyo (TYO: 4568) has announced that it has received marketing approval...

Posts pagination

1 … 266 267 268 … 696

Recent updates

  • InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor
  • Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B
  • Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches
  • China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline
  • Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for HBM7575/SKB575, Long-Acting Bispecific Antibody for Asthma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare Pharma’s Soficitinib Meets Primary Endpoint in Phase III Atopic Dermatitis Trial as Highly Selective TYK2 Inhibitor

Company Drug

Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B

Company

Boehringer Ingelheim Reports 16.2% H1 2026 Sales Growth Driven by JARDIANCE and New Oncology Launches

Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.